Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.


Clinical Trial Description

Choroidal neovascularization is a hallmark of angioid streaks, and presumably VEGF-driven. Ranibizumab has been shown to be effective in CNV secondary to age-related macular degeneration. Therefore, we hypothesize that ranibizumab may be efficacious in the treatment of CNV secondary to angioid streaks ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01015495
Study type Interventional
Source University of Illinois at Chicago
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date December 2009
Completion date January 2011

See also
  Status Clinical Trial Phase
Completed NCT00406250 - Intravitreal Bevacizumab in Agioid Streaks Phase 1
Terminated NCT00599820 - Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks Phase 3
Withdrawn NCT01256580 - Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD N/A